<DOC>
	<DOCNO>NCT02626169</DOCNO>
	<brief_summary>Ticagrelor clopidogrel FDA-approved drug inhibition platelet hyper-reactivity certain clinical situation . The platelet inhibition patient outcome ( PLATO ) trial show patient acute coronary syndrome , ticagrelor significantly reduce primary endpoint ( cardiovascular death , myocardial infarction stroke ) , all-cause mortality cardiovascular mortality compare clopidogrel . It suggest addition anti-platelet effect , ticagrelor additional unique effect , include anti-inflammatory effect share clopidogrel . In present study investigator assess whether ticagrelor , compare clopidogrel , increase serum level 15-epi-lipoxin A4 , potent endogenous anti-inflammatory mediator .</brief_summary>
	<brief_title>The Effect Ticagrelor 15-Epi-Lipoxin A4 Inflammation</brief_title>
	<detailed_description>Clopidogrel , ticagrelor prasugrel routinely use platelet inhibition addition aspirin patient acute coronary syndrome . The platelet inhibition patient outcome ( PLATO ) trial show patient acute coronary syndrome , ticagrelor significantly reduce primary endpoint ( cardiovascular death , myocardial infarction stroke ) , all-cause mortality cardiovascular mortality compare clopidogrel . On hand , compare clopidogrel patient acute coronary syndrome schedule percutaneous coronary intervention , prasugrel therapy affect overall mortality despite fact associate significantly reduce rate ischemic event , include stent thrombosis , increase risk major bleeding , include fatal bleeding . This may suggest ticagrelor posse additional ( pleiotropic ) effect besides platelet inhibition . The investigator recently show pioglitazone increase 15-epi-lipoxin A4 blood level patient . The investigator recently find rat , ticagrelor increase tissue level 15-epi-lipoxin A4 heart , aorta kidney . It plausible favorable effect ticagrelor see clinical study mediate via anti-inflammatory effect 15-epi-lipoxin A4 . 15-epi-lipoxin A4 potent anti-inflammatory inflammation-resolving mediator derive arachidonic acid . Several study suggest ticagrelor anti-inflammatory property various animal model . In present study investigator assess ticagrelor increase blood 15-epi-lipoxin A4 level dos use patient .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Lipoxin A4</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Women childbearing potential must use acceptable method contraception avoid pregnancy throughout study Patients stable coronary artery disease ( 312 month Acute Coronary Syndrome ) receive clopidogrel least 3 month . Recent stroke acute coronary syndrome ( &lt; 3 month randomization ) . Concurrent use aspirin &gt; 100 mg/day dose reduction 81 mg/day contraindicate . Current use theophylline . Concurrent use Non Steroidal AntiInflammatory Drugs . Patients receive follow medication : ketoconazole , itraconazole , voriconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , telithromycin , rifampin , dexamethasone , phenytoin , carbamazepine , phenobarbital . Patients receive simvastatin lovastatin dos great 40 mg daily . Patients type 2 diabetes fast plasma glucose great 200 mg/dl . Active inflammatory disease chronic infection . Contraindication aspirin , clopidogrel ticagrelor . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>15-epi-lipoxin A4</keyword>
	<keyword>inflammation</keyword>
	<keyword>atherosclerosis</keyword>
</DOC>